Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Invasive ductal carcinoma (IDC) is characterized by the uncontrolled growth and spread of malignant cells that have breached the walls of the milk ducts, allowing them to infiltrate the surrounding breast tissue. At Alfa Cytology, our team of experienced biologists work with you to develop invasive ductal carcinoma therapeutics.
Invasive ductal carcinoma (IDC) is the most common form of breast cancer, accounting for approximately 80% of all breast cancer diagnoses. This aggressive subtype of breast cancer originates in the milk ducts and then invades the surrounding breast tissue. According to the latest epidemiological data, the incidence of invasive ductal carcinoma has remained relatively stable in recent years, with an estimated 180,000 new cases diagnosed annually in the United States alone. Increasing incidence of IDC across the globe due to factors such as aging population, changing lifestyles, and heredity has greatly contributed to the expansion of the breast cancer treatment market.
Researchers are actively involved in several clinical trials exploring innovative approaches to the treatment of invasive ductal carcinoma. These trials are designed to evaluate the safety and efficacy of novel therapeutic agents, combination therapies, and advanced diagnostic techniques.
| NCT | Therapy | Therapeutics | Phase |
| NCT01953588 | Neoadjuvant Endocrine Therapy | Fulvestrant + Anastrozole | |
| NCT03947151 | Endocrine Therapy | Degarelix |
As a leading preclinical contract research organization (CRO), Alfa Cytology has established a strong reputation for its expertise in invasive ductal carcinoma research. The company's multidisciplinary team of scientists and regulatory specialists collaborate seamlessly to provide comprehensive and tailored solutions for clients in the pharmaceutical and biotechnology industries.
Therapeutics Development
Xenograft Model Development |
Genetic Engineering Model Development |
| Optional Cell Lines: BT20, BT474, MCF-7, MDA-MB-435, SUM1315, ZR-75-1, Others | Optional Transgene: PyMT, SV40, Others |
By collaborating with Alfa Cytology, clients gain access to a comprehensive suite of services tailored to the unique needs of invasive ductal carcinoma research and development. From preclinical study design and execution to data analysis, the company's team of experts is dedicated to empowering clients' efforts in bringing transformative invasive ductal carcinoma therapies to market. If you are interested in our service, please contact us.
Reference
